The Journal of Medical Case Reports (JMCR) last week published its 1000th case report. This
coincides with the anniversary of the journal’s launch three years ago,
in February 2007. We would like
to thank all our authors, reviewers and Editorial Board members, whose
continued support of the journal has been essential in reaching this
With 1000 cases across all medical disciplines it may be too soon to challenge established evidence-based medicine practices with published "experiences", but the growth of the journal surely challenges traditionally-held
views about the place of case reports in the literature. It also reinforces the need for case reporting as a catalyst for
clinical hypothesis and experimental research, and the value
Muscle mRNA expression is invariant with respect to diabetes status, but coordinated changes in numerous microRNAs may control protein abundance and affect skeletal muscle insulin resistance, according to research recently published in Genome Medicine.
Muscle insulin resistance is a condition characterised by normal levels of insulin but a reduction in muscle glucose uptake, which can lead to high blood glucose concentration and is a contributing factor in type 2 diabetes.
In their article “Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in Type 2 Diabetes”, James Timmons and colleagues report a study in which they used gene-chips to examine mRNA and miRNA levels in patients with type 2 diabetes compared to healthy controls. …
In the developed world, we generally tend to take pain treatment and management for granted; if we’re in physical pain, someone will provide treatment to do something about it. It’s easy to lose sight of the fact that this is not neccessarily true across the globe. In a new debate published in BMC Medicine, Lohman and colleagues, from Human Rights Watch examine the issues related to access to adequate pain treatment, and why barriers to pain treatment can be tantamount to a violation of human rights.
Check out the full article: “Access to pain treatment as a human right”, and while you’re visiting BMC Medicine, why not sign up for article alerts, which will …
In a paper recently published in Genome Biology, Robert Nicol and colleagues from the Broad Institute in Massachusetts, report a new method for reducing the time and cost associated with 454 sequencing.
The recent revolution in next-generation sequencing technologies impacted significantly on the genomics field, dramatically reducing the cost of sequencing large genomes, such as those of mammals – the recently published giant panda genome was sequenced entirely using Illumina short-read sequence data. However, this reduction in cost is less apparent for small or medium-sized genomes, where to run a single lane or channel on a sequencer would result in a vast over-coverage of sequence data, reducing the cost-effectiveness of the process. In addition, manual preparation of the …
Until recently, microarrays have been the method of choice for transcriptional profiling. The advent of next generation sequencing technologies however has seen the rise of direct sequencing of mRNA (RNA-seq) as a new method for such profiling. In a recent publication in Genome Biology, Alicia Oshlack and colleagues at the Walter and Eliza Hall Institute in Melbourne, Australia have developed a new method for performing Gene Ontology analysis of RNA-seq data, called GOseq.
GOseq identifies whether a given transcriptional profile is over-represented with transcripts associated with specific biological processes. Up until now, statistical methods, such as this, used for analysing RNA-seq data have generally been modifications of methods developed for use with microarray …
The UK government has in
recent years made significant amounts of government data openly available for
reuse. They Work for You is an example of a
website which creatively reuses data on UK parliamentary activity, and its parent organization, MySociety, has played an important role in
encouraging the UK government towards opening up more data.
The latest development in
UK government open data sharing is the launch
of data.gov.uk, launched in beta test form
last month , which “provides a single access point to over 2,500 central
government datasets that have been made available for free re-use”.
Buried in the small print
of this announcement is an important change, with significant implications …
An increasing number of peer-reviewed journals and research funding
agencies require authors to make available the raw, unprocessed data
supporting the findings reported in their research articles (click here for
information on why this is important). Just this month, for example, The
American Naturalist announced
that its authors must make their data publicly available as a condition of
publication and the UK Government has also recently launched an open data website.
But there is little
practical guidance available on how data should be shared,
particularly in clinical research where sharing information about
individuals without their consent presents risks to privacy – both from a
legal and ethical perspective.
Recognizing this problem, in March
2009 the editors …
Harm Reduction Journal and International Journal
for Equity in Health have both been accepted for inclusion by Thomson
Reuters and are due to receive their first impact factors in June 2011. Harm
Reduction Journal, which is overseen by Ernest Drucker has an
unofficial 2008 impact factor of 1.68, and International Journal of Equity in
Health which is lead by Barbara Starfield, has an unofficial impact factor
of 1.24. Both journals have also been accepted for coverage in Current
We would like to congratulate the Editors-in-Chief of these journals on this achievement and look forward to receiving the official
impact factors for both titles in due course.
A Method recently published in Genome Medicine suggests that inclusion of phenotypic and genotypic information from close relatives in a genetic risk prediction model can lead to improved estimates of an individual’s disease risk.
Douglas Ruderfer, Joshua Korn and Shaun Purcell, from Massachusetts General Hospital, The Broad Institute of Harvard and MIT, and Harvard Medical School have developed a liability threshold model which predicts an individual’s risk of developing a complex disease, using their own genotype as well as that of a close relative whose disease phenotype is known. “Family-based genetic risk prediction of multifactorial disease” is published in the January issue of Genome Medicine.
The authors say, ‘we do not ask “how well do SNPs …
Alzheimer’s disease is thought to affect 37 million people worldwide, and there is evidence to suggest that inflammation can contribute to Alzheimer’s and exacerbate the course of the disease. A review published in Alzheimer’s Research & Therapy discusses inflammatory reactions in Alzheimer’s, which are still considered to be downstream effects of the accumulated proteins believed to trigger disease – amyloid beta and tau.
But the more recent “inflammation hypothesis” suggests it may be possible to alter the immune system and direct it towards the clearance of these amyloid and tau proteins. Anti-inflammatory drugs and immunization against amyloid beta have been considered but initial clinical trials have shown mixed results.